Conclusion: Navigating Texas Compounding Pharmacy in 2026 with Confidence The Texas compounding pharmacy landscape in 2026 is defined by significant regulatory change (TSBP 291.133, effective March 1, 2026), a major market disruption (the GLP-1 compounding shutdown), important patient protections (SB 1236 PBM reform), and rising quality standards (PCAB accreditation and USP / / )
Since peptides are naturally occurring and have specific functions, they are generally well tolerated by the body and have minimal to no side effects
For people taking a GLP-1, powders can be especially useful because they make it easier to top up protein in smaller, more tolerable amounts when appetite is low
For DHA and d5-DHA data were acquired in negative mode using full scan with a mass range of m/z 326335 at a resolution of 30,000
A crucial knowledge gap is the lack of head-to-head comparative studies evaluating their ocular effects